Fiche publication
Date publication
août 2026
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CONROY Thierry
,
Pr HARLE Alexandre
,
Dr LAMBERT Aurélien
,
Dr WITZ Andréa
Tous les auteurs :
Witz A, Conroy T, Lambert A, Salleron J, Diallo A, Husson M, Nicolle R, Hammel P, Biagi J, Renouf DJ, Turpin A, Richard C, Bachet JB, Iovanna J, Dusetti N, Monard L, Mauduit M, Cros J, Harlé A
Lien Pubmed
Résumé
Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX/mFFX) is the standard adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma (PDAC), offering survival benefits over gemcitabine (GEM). However, the contribution of molecular biomarkers to treatment selection remains unclear. Here, we characterize the molecular landscape of tumors from the PRODIGE-24/CCTG PA6 trial and assess the clinical impact of genomic alterations and molecular subtypes.
Référence
J Clin Oncol. 2026 08 3;:JCO2502508
